ABSTRACT
Doxapram was first introduced into the market as an analeptic with the capacity to stimulate respiration in 1962. Subsequently, doxapram was proved to be beneficial as an adjunct in a variety of conditions requiring respiratory stimulation where complications may arise with the use of standard procedures such as mechanical ventilation or oxygen administration. At present doxapram is relegated to serve as an adjunct to other forms of therapy in pediatric patients. The pharmacological action of doxapram on the respiratory system is selective. In a series of studies, P. K. Gupta and J. W. Dundee demonstrated the ability of doxapram to block the respiratory depression induced by morphine without affecting the analgesia produced by the narcotic. The cardiovascular system is also a target organ affected by doxapram. Further extensive study is needed to establish that doxapram is of benefit as an adjunct to methylated xanthines in the treatment of apnea of prematurity.
